Proqr Therapeutics N V (PRQR)

Jan 31, 2025

ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of “Buy” by Brokerages - Defense World

Jan 31, 2025

Jan 27, 2025

Ballentine Partners LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jan 27, 2025

Jan 23, 2025

Analysts Offer Predictions for PRQR FY2025 Earnings - Defense World

Jan 23, 2025

Jan 14, 2025

ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update - MarketBeat

Jan 14, 2025

Jan 13, 2025

ProQR Therapeutics' SWOT analysis: RNA editing firm's stock poised for growth - Investing.com

Jan 13, 2025

Jan 12, 2025

Oppenheimer Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jan 12, 2025

Jan 09, 2025

ProQR Therapeutics (NASDAQ:PRQR) Receives $7.60 Consensus Target Price from Analysts - Defense World

Jan 09, 2025

Jan 06, 2025

ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat

Jan 06, 2025

Dec 19, 2024

BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Dec 19, 2024

Dec 17, 2024

ProQR Therapeutics' SWOT analysis: RNA-editing stock poised for clinical leap - Investing.com

Dec 17, 2024

Dec 15, 2024

ProQR Therapeutics’ (PRQR) “Market Outperform” Rating Reiterated at JMP Securities - Defense World

Dec 15, 2024

Dec 15, 2024

ProQR Therapeutics’ (PRQR) Buy Rating Reiterated at HC Wainwright - Defense World

Dec 15, 2024

Dec 14, 2024

ProQR Therapeutics (NASDAQ:PRQR shareholders incur further losses as stock declines 21% this week, taking five-year losses to 70% - Simply Wall St

Dec 14, 2024

Dec 14, 2024

Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% Pounding - Simply Wall St

Dec 14, 2024

Dec 14, 2024

ProQR Therapeutics (NASDAQ:PRQR) Earns “Buy” Rating from Chardan Capital - Defense World

Dec 14, 2024

Dec 13, 2024

Leiden-based biotech company ProQR bags €7.7M - Silicon Canals

Dec 13, 2024

Dec 12, 2024

ProQR shares hold price target, buy rating on RNA tech optimism - Investing.com

Dec 12, 2024

Dec 12, 2024

JMP Securities Reiterates Market Outperform Rating for ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat

Dec 12, 2024

Dec 12, 2024

ProQR Therapeutics (NASDAQ:PRQR) Receives "Buy" Rating from Chardan Capital - MarketBeat

Dec 12, 2024

Dec 12, 2024

ProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC Wainwright - MarketBeat

Dec 12, 2024

Dec 12, 2024

ProQR Therapeutics announces $8.1M in new funding from RSRT - Yahoo Finance

Dec 12, 2024

Dec 12, 2024

RNA specialist ProQR Therapeutics NV bags US$8.1m funding - European Biotechnology News

Dec 12, 2024

Dec 12, 2024

ProQR secures $9.1M for Rett syndrome trial By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 11, 2024

ProQR secures $9.1M for Rett syndrome trial - Investing.com India

Dec 11, 2024

Dec 11, 2024

ProQR Therapeutics Announces $8.1 Million in New Funding - GlobeNewswire

Dec 11, 2024

Dec 11, 2024

ProQR Secures $8.1M Funding Boost to Advance Revolutionary Rett Syndrome Treatment - StockTitan

Dec 11, 2024

Dec 10, 2024

ProQR Therapeutics' SWOT analysis: RNA editing stock faces pivotal clinical phase - Investing.com

Dec 10, 2024

Dec 10, 2024

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist - The Manila Times

Dec 10, 2024

Dec 10, 2024

ProQR Therapeutics Strengthens RNA Editing Leadership with Key ADAR Expert Appointment - StockTitan

Dec 10, 2024

Dec 06, 2024

ProQR Therapeutics price target raised to $8 from $5 at JMP Securities - Yahoo Finance

Dec 06, 2024

Dec 05, 2024

ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 - GlobeNewswire

Dec 05, 2024

Nov 30, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.com - Defense World

Nov 30, 2024

Nov 24, 2024

OneDigital Investment Advisors LLC Boosts Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Nov 24, 2024

Nov 21, 2024

ProQR Therapeutics NV (MEX:PRQR) Earnings Yield % : N/A% (As of Nov. 21, 2024) - GuruFocus.com

Nov 21, 2024

Nov 21, 2024

RNA Editing Market Top Companies StudyProQR Therapeutics NV, - openPR

Nov 21, 2024

Nov 21, 2024

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageTime to Sell? - MarketBeat

Nov 21, 2024

Nov 20, 2024

ProQR Therapeutics NV (MEX:PRQR) 50-Day SMA : MXN35.82 (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024

Nov 20, 2024

ProQR Therapeutics NV (FRA:0PQ) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 20, 2024

ProQR Therapeutics NV (FRA:0PQ) 3-Year EBITDA Growth Rate : 31.80% (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 20, 2024

ProQR Therapeutics NV (FRA:0PQ) 3-Year Book Growth Rate : -26.20% (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 14, 2024

ProQR Therapeutics NV (MEX:PRQR) Cash Flow from Financing : MXN-38.6 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Chardan Capital Issues Pessimistic Outlook for PRQR Earnings - Defense World

Nov 14, 2024

Nov 13, 2024

What is Chardan Capital's Forecast for PRQR FY2024 Earnings? - MarketBeat

Nov 13, 2024

Nov 09, 2024

ProQR Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

ProQR: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 08, 2024

Nov 08, 2024

ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00 at HC Wainwright - MarketBeat

Nov 08, 2024